We might also assume this is really happening, because it was placed in an SEC filing, and half year negotiations continued after the 10Q heads up, because the evergreen reinstitution filing seemed to be indication that boxes were being checked.
1. So how do you take a half year negotiation and complete it before phase III results. You would need to have an IA available to look at, right?
2. Or you would need to be so scared that you don't know the answer and simply want to dish the unveiling on someone with bigger resources to handle the uncertainty.
I don't think any big pharma touches this without #1 above.
Assume an IA is very good. It would simply mean the final will be better. What Pharmas need a big shot in the arm right now for their CI program? That's easy. BMY, Astra and Roche. Who does not? That's easy too. Merck.
Frankly, whether you like LP or not, it doesn't matter, what LP and Pharma might be thinking is this needs to get done before results are released because hedge funds would eat up NWBO after results, just like they ate up Dendreon.
Pharma would be interested to have the 36 month final topline (and analysis) for appraisal purposes, but they would not need it to figure out what NWBO is worth to them. In other words, neither party would need or want to see what the market does with a trial success before a deal is done. It's like handing fate to the wild west.
The more adult thing to do would be to negotiate now, if an IA was available, knowing full well that the data will get even better, and by how much. Finish the deal before then. Let pharma handle the unblinding and final commercialization readiness. Keep Dr. Bosch, Dr. Maida, Dr. Boynton and a couple other key players.
Just spit ballin'.
Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
